pyrazines has been researched along with Osteosclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J; Zhou, DB | 1 |
| Auradé, F; Chaligné, R; Gastinne, T; Giraudier, S; Gonin, P; Lacout, C; Pisani, DF; Tulliez, M; Vainchenker, W; Villeval, JL; Wagner-Ballon, O | 1 |
1 review(s) available for pyrazines and Osteosclerosis
| Article | Year |
|---|---|
New advances in the diagnosis and treatment of POEMS syndrome.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Boronic Acids; Bortezomib; Castleman Disease; Chromosome Aberrations; Combined Modality Therapy; Dexamethasone; Disease Management; Drug Therapy, Combination; Genes, Immunoglobulin; Humans; Hypertension, Pulmonary; Lenalidomide; Melphalan; Osteosclerosis; Peripheral Blood Stem Cell Transplantation; Plasma Cells; POEMS Syndrome; Prognosis; Pyrazines; Severity of Illness Index; Symptom Assessment; Thalidomide; Transplantation, Autologous; Vascular Endothelial Growth Factor A | 2013 |
1 other study(ies) available for pyrazines and Osteosclerosis
| Article | Year |
|---|---|
Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice.
Topics: Animals; Boronic Acids; Bortezomib; Disease Models, Animal; Mice; NF-kappa B; Osteosclerosis; Primary Myelofibrosis; Protease Inhibitors; Pyrazines; Survival Rate; Thrombopoietin | 2007 |